Marketing approvals for generic drugs may soon be delinked from their patent status in India. This comes as a result of long-standing demand from India’s pharmaceutical industry, which depends heavily on the sale of generic drugs.
India to delink marketing authorisation and patent status
Home/Policies & Legislation
|
Posted 07/01/2011
0
Post your comment
The health ministry is planning to remove a question on the patent status of a drug from the form that medicine companies fill in when applying to the Drug Controller General of India (DCGI) for regulatory approval, a ministry official said.
The proposal follows a meeting in Mumbai, India, in November 2010 between Indian drugmakers and Health Minister Ghulam Nabi Azad.
If deleted, the DCGI will issue approvals only on the grounds of drug quality and efficacy.
The issue will be taken up at the next Drug Testing Advisory Board meeting.
Source: Livemint
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Reports
FTC reveals extent of PBM drug mark-ups and profits
Latin American patients face 4.7-year wait for innovative treatments
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
NPRA Malaysia trials new timelines for variation applications
Home/Policies & Legislation Posted 05/11/2024
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Home/Policies & Legislation Posted 18/09/2024
China’s NMPA expands global ties with the Netherlands and Indonesia
Home/Policies & Legislation Posted 04/09/2024
Japan's PMDA expands influence with new office in Thailand
Home/Policies & Legislation Posted 06/08/2024
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment